Kurowska-Stolarska M, Kewin P, Murphy G, Russo RC, Stolarski B, Garcia CC et al
Persico, Marco, Raffaele Sessa, Elena Cesaro, Irene Dini, Paola Costanzo, Alberto Ritieni, Caterina Fattorusso, and Michela Grosso
Most people on GLP-1 medications aren't skipping protein deliberately
Experimental studies in animal models indicate that IL-1 acts upstream of other proinflammatory cytokines, as the administration of an IL-1 receptor antagonist not only attenuates neurodegeneration but also significantly reduces TNF- and IFN- protein levels in the mesencephalon [195]
FDA steps up enforcement The FDA has since sent warning letters to 30 telehealth firms and restricted the use of GLP-1 active pharmaceutical ingredients in unapproved compounds
The effect is consistent and measurable, contributing significantly to the weight-loss results seen across clinical trials